Comparable stake leader
Gail Cawkwell
SEC ownership of INTERCEPT PHARMACEUTICALS, INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001270073.
Disclosed value leader
Gail Cawkwell
Comparable rows
0/3
Latest evidence
11 Jul 2022
- Parsed ownership sources
-
3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Gail Cawkwell
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
11 Jul 2022
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001270073
- Issuer location
- Morristown, NJ
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of INTERCEPT PHARMACEUTICALS, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Gail Cawkwell
Disclosed value leader
Gail Cawkwell
Comparable rows
0/3
Latest evidence
11 Jul 2022
3/4/5
Highest disclosed value: $679,060
3 rows are not safely comparable across share classes.
Quick read
Gail Cawkwell has the largest disclosed position value at $679.1K.
0 of 3 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Gail Cawkwell's linked filing trail.
Disclosed position value
Top 3
Gail Cawkwell
$679.1K
Bryan Ball
$478.4K
Lisa M. DeFrancesco
$195.9K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-3 of 3 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Gail Cawkwell |
3/4/5
SVP, Med Affairs, Safety & PV
|
—
mixed-class rows
|
$679,060
47,040 shares
mixed-class rows
|
— | 12 Feb 2022 |
| Bryan Ball |
3/4/5
Chief Qual. Officer & SVP Ops.
|
—
class O/S missing
|
$478,382
25,178 shares
|
— | 11 Jul 2022 |
| Lisa M. DeFrancesco |
3/4/5
SVP, IR & Corp. Affairs
|
—
class O/S missing
|
$195,852
10,308 shares
|
— | 31 Dec 2021 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 07 Jul 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 20 reporting-owner rows connected to INTERCEPT PHARMACEUTICALS, INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
20
Largest Forms 3/4/5 holder
Gail Cawkwell
Net 12M change
$0
Latest report
08 Nov 2023
Recent insider transactions for INTERCEPT PHARMACEUTICALS, INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.